



Press release

MEDIAN Technologies strengthens its medical expertise department by appointing Dr. Nathalie Faye as Medical Director Europe

SOPHIA ANTIPOLIS, France –July 12, 2016– MEDIAN Technologies (ALMDT), a leading medical imaging solutions and service provider for image interpretation and management in oncology, today announces the appointment of Dr. Nathalie Faye, M.D as the company's Medical Director, Europe.

Dr. Faye joins MEDIAN Technologies to strengthen the medical expertise department, and will work under the responsibility of Dr. Souhil Zaim, MEDIAN's chief medical officer. As an imaging expert, she will be involved in all Europe based operations led by MEDIAN Technologies, focusing on clinical trial operations. Dr. Faye will be also involved in MEDIAN's R&D activities where her imaging expertise will be an asset in the development of MEDIAN proprietary Lesion Management Solutions (LMS) new functionalities and extension to other therapeutic areas.

Dr. Faye, MD, PhD is a board certified radiologist with over 10 years of experience in imaging for clinical trials with the biopharmaceutical industry. Prior to joining MEDIAN Technologies, Dr. Faye was assistant professor of radiology (2011-2013) at the university hospital of Lille, France. She had worked previously as a visiting fellow and expert reader at Synarc, San Francisco, California, USA (2005-2012) and MEDIAN (since 2014).

Dr. Faye received her medical degree and completed her radiology residency and fellowship at the University of Paris, School of Medicine, France. She was assistant professor at the department of radiology at the Curie Institute, Paris (France). She also obtained a master and a doctorate degree in medical imaging (focused on functional and cellular imaging) in Paris.



About MEDIAN Technologies: MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. MEDIAN Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. MEDIAN serves two primary markets: drug development and patient care. MEDIAN has a strategic partnership with the world's largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors

worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, MEDIAN Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. MEDIAN has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia. MEDIAN has received the label "Innovative company" by the BPI and is listed on Euronext Paris' Alternext market. ISIN: FR0011049824– ticker: ALMDT. The company is eligible for the PEA PME SME equity savings plan setup. For more information on MEDIAN, please visit: www.medianttechnologies.com



MEDIAN®

“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”



Contacts

MEDIAN Technologies Fredrik Brag, CEO +33 4 92 90 65 82 fredrik.brag@mediantechnologies.com	Press ALIZE RP Caroline Carmagnol / Wendy Rigal + 33 1 44 54 36 66 median@alizerp.com	Investors ACTIFIN Ghislaine Gasparetto +33 1 56 88 11 11 ggasparetto@actifin.fr
--	---	---